Blackstone Inc’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.6M Buy
+237,108
New +$15.8M 0.07% 72
2026
Q1
Sell
-1,165,408
Closed -$35.3M 493
2025
Q4
$35.3M Buy
1,165,408
+315,008
+37% +$8.78M 0.14% 63
2025
Q3
$16.4M Buy
850,400
+23,676
+3% +$351K 0.07% 84
2025
Q2
$9.27M Buy
826,724
+43,071
+5% +$449K 0.04% 87
2025
Q1
$8.04M Buy
783,653
+543,479
+226% +$6.78M 0.03% 83
2024
Q4
$4.66M Buy
+240,174
New +$5.86M 0.02% 99

Other funds holding ORKA

Blackstone Inc's ORKA Position: Q2 2026 in Review

Blackstone Inc opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 237,108 shares worth $22.6M. The stake represents 0.07% of the portfolio and ranks #72 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in ORKA as recently as Q4 2025.

Blackstone Inc first reported a position in ORKA in Q4 2024 and has held it in 6 quarters since. The position peaked at $35.3M in Q4 2025. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Blackstone Inc held 237,108 shares of Oruka Therapeutics worth $22.6M as of Q2 2026.
  • Oruka Therapeutics was a new Blackstone Inc position in Q2 2026.
  • Oruka Therapeutics made up 0.07% of Blackstone Inc's portfolio in Q2 2026, its #72 holding.
  • Blackstone Inc first reported a position in Oruka Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Blackstone Inc's Oruka Therapeutics position peaked at $35.3M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.